AKR1B10 在肝癌和肝病变中的表达及其临床意义
| 作者: |
1曲丹华,
2王春宇,
3王学敏,
4信瑞
1 吉林大学第二医院呼吸与危重症医学科，长春 130021 2 吉林大学第二医院放疗科，长春 130021 3 陕西省肿瘤医院放疗医院放射治疗科，西安 710000 4 吉林大学第二医院放射线科，长春 130021 |
| 通讯: |
信瑞
Email: xin-1017@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2018.06.009 |
摘要
目的：探究醛酮还原酶家族1成员10(Aldo-keto reductase family 1 member B10，AKR1B10)在肝癌和肝病变组织中的表达情况，阐明AKR1B10在肝癌发病过程中的作用。方法：收集2013年 3月至2016年5月间吉林大学第二医院肝胆外科收集的石蜡包埋病理切片和相关病理资料127例，其中肝癌61例、肝良性非肿瘤性病变54例及肝良性占位性病变12例，采用免疫组织化学方法检测AKR1B10在肝癌组织、肝良性非肿瘤性病变组织和肝良性占位性病变组织中的表达，分析其与其他临床病理资料的相关性。结果：肝良性占位性病变组织、肝良性非肿瘤性病变组织和肝癌组织中AKR1B10依次升高，3组间差异均有统计学意义(P<0.05)。肝良性非肿瘤性病变组织中AKR1B10与患者的年龄、性别、吸烟、饮酒等临床资料无相关性(P>0.05)；与血清甲胎蛋白水平和肝细胞脂肪变性比例呈正相关(r=0.539，P=0.002；r=0.306，P=0.004)。结论：AKR1B10在肝癌组织和肝良性非肿瘤性病变组织中呈现高表达，并与甲胎蛋白水平和肝细胞脂肪变性比例呈正相关，可成为肝癌早期诊断的分子标志物。
关键词：
AKR1B10；肝癌；免疫组织化学；临床意义
Expression and clinical significance of AKR1B10 in hepatocarcinogenesis
CorrespondingAuthor: XIN Rui Email: xin-1017@163.com
DOI: 10.3978/j.issn.2095-6959.2018.06.009
Abstract
Objective: To investigate the expression level of Aldo-keto reductase family 1 member B10 (AKR1B10) in hepatocellular carcinoma and ominous liver lesions, and to evaluate the role of AKR1B10 in the pathogenesis of hepatocellular carcinoma. Methods: Paraffin-embedded sections and pathological data were collected from 127 patients between March 2013 and May 2016 in the Second Hospital of Jilin University, including 61 cases of hepatocellular carcinoma tissue, 54 cases of hepatic benign non-tumor lesions and 10 benign liver lesions. Immunohistochemistry was used to detect the expression of AKR1B10 in hepatocellular carcinoma tissue, hepatic benign non-tumor lesions and benign liver lesions. Results: The expression levels of AKR1B10 in benign liver lesions, hepatic benign non-tumor lesions and hepatocellular carcinoma tissue were increased in turn, the difference among three groups were statistically significant (P<0.05). In hepatic benign non-tumor lesions, the expression level of AKR1B10 had no correlation with patients clinical data including age, gender, smoking, drinking (P>0.05); but had positively correlated relationship with serum AFP levels and hepatic steatosis (r=0.539, P=0.002; r=0.306, P=0.004). Conclusion: AKR1B10 presents high expression in hepatocellular carcinoma and hepatic benign non-tumor lesions tissue, and is positively correlated with and AFP level and hepatic steatosis which may play an important role in the pathogenesis of hepatocellular carcinoma.
Keywords：
AKR1B10; hepatocellular carcinoma; immunohistochemistry; clinical significance